Effect of Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Booster on Human Immunodeficiency Virus Reservoirs and Immune Markers

M Ali Rai; Victoria Shi; Brooke D Kennedy; Jesse S Justement; Kathleen Gittens; Genevieve McCormack; Jana Blazkova; Susan Moir; Tae-Wook Chun

doi:10.1093/ofid/ofac544

Effect of Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Booster on Human Immunodeficiency Virus Reservoirs and Immune Markers

Open Forum Infect Dis. 2022 Oct 17;9(11):ofac544. doi: 10.1093/ofid/ofac544. eCollection 2022 Nov.

Authors

M Ali Rai¹, Victoria Shi¹, Brooke D Kennedy¹, Jesse S Justement¹, Kathleen Gittens², Genevieve McCormack¹, Jana Blazkova¹, Susan Moir¹, Tae-Wook Chun¹

Affiliations

¹ Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
² Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.

Abstract

We investigated effects of the severe acute respiratory syndrome coronavirus 2 (SARV-CoV-2) booster vaccination on human immunodeficiency virus (HIV) reservoir size, immune markers, and host immune responses in people with HIV receiving antiretroviral therapy. Our data suggest that the SARS-CoV-2 booster vaccine is not likely to replenish the persistent HIV reservoir nor provide an immunologic environment to facilitate active HIV expression/replication.

Keywords: HIV; HIV reservoirs; SARS-CoV-2; booster vaccine; immune markers and responses.

Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.